Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rockwell Automation (ROK) vs BIO-TECHNE Corp (TECH) Price & Performance

Rockwell AutomationTrade
BIO-TECHNE CorpTrade

Price performance (Past 24H)

Key statistics

Rockwell Automation vs BIO-TECHNE Corp — how do they compare? Rockwell Automation trades at $466.05 (market cap $51.04B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: Rockwell Automation is far larger — about 4.6× BIO-TECHNE Corp's market cap, and Rockwell Automation pays the higher dividend (1.2%). Which is the better fit depends on your goals.

ROKTECH
Market Cap
$51.04B$11.16B
Sector
IndustrialsHealth
52-Week High
$495.08$72.12
52-Week Low
$328.67$43.31
Enterprise Value
$54.67B$11.24B
Dividend Yield
1.2%0.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rockwell Automation

Rockwell Automation (ROK) trades at $459.09, down 0.6% on the day, with a neutral technical signal despite bullish moving averages. The company maintains strong profitability with 48.9% gross margins and has beaten earnings estimates for three consecutive quarters. Recent developments include partnerships in nuclear automation and recognition as a Global Lighthouse facility, positioning ROK for AI infrastructure growth.

ROK presents a mixed outlook with premium valuation metrics (P/E 48) offset by consistent earnings beats and AI-driven growth potential. Key risks include cyclical industrial exposure and competitive pressures, while analyst consensus at $471.71 suggests modest upside from current levels with 31% buy ratings indicating cautious optimism.

BIO-TECHNE Corp

Bio-Techne (TECH) trades at $71.64, down 0.67% today, near its 52-week high following Merck KGaA's $73 per share acquisition offer. The stock shows bullish technical signals with strong moving averages, though RSI indicates overbought conditions. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains solid gross margins of 64.96% but faces declining net income margins, down to 6.01% in 2025 from 25.09% in 2023.

The outlook is heavily influenced by the pending acquisition, offering a clear exit near current levels. Risks include shareholder litigation over deal fairness and fundamental profitability pressures. With a high P/E of 103.03, the stock's upside appears capped without the deal, while the $73 bid provides a near-term floor. Investors should weigh acquisition completion probability against operational challenges.

Returns comparison

Trailing returns across standard periods

About Rockwell Automation

Rockwell Automation is a pure-play automation competitor that is the successor entity to Rockwell International, which spun off its former Rockwell Collins avionics segment in 2001. As of fiscal 2021, the firm operates through three segments--intelligent devices, software and control, and lifecycle services. Intelligent devices contains its drives, sensors, and industrial components, software and control contains its information and network and security software, while lifecycle services contains its consulting and maintenance services as well as its Sensia JV with Schlumberger.

Read more on ROK

About BIO-TECHNE Corp

Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.

Read more on TECH